Filtering

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()

DOP076

A Danish cross-sectional study: autoimmune and chronic inflammatory disorders associated with ulcerative colitis.

Year: 2016
Authors:

M. Halling1, T. Knudsen2, J. Kjeldsen1, J. Nielsen3, L. Koch Hansen*4

1Odense University Hospital, Department of Gastroenterology, Odense, Denmark, 2Esbjerg Hospital, Dept. of Gastroenterology and Hepatology, Esbjerg, Denmark, 3Odense University Hospital, Department of Clinical Epidemiology, Odense, Denmark, 4Vejle Hospital, Dept. of Gastroenterology and Hepatology, Vejle, Denmark

DOP077

Immunochip analysis identifies multiple susceptibility loci for collagenous colitis

Year: 2016
Authors:

G. Roda*1, H. Jianzhong2, Z. Zhongyang3, J. Torres1, A. Chen4, R. Petras5, D. Pardi6, A. Juga7, G. Levi3, W. Cao8, F. Rieder9, I. Gordon10, K. Hao3, N. Harpaz11, J. Cho12, J.-F. Colombel12, I. Peter3

1Icahn School of Medicine, Gastroenterology, New York, New York, United States, 2Icahn School of Medicine, New York, New York, United States, 3Icahn School of Medicine at Mount Sinai, Medicine, New York, New York, United States, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, New York, United States, 5Ameripath, Pathology, Cleveland, Ohio, United States, 6Mayo Clinic, Gastroenterology, Rochester, Minnesota, United States, 7New York-Presbyterian, Pathology, New York, New York, United States, 8University of Rochester, Pathology, Rochester, Minnesota, United States, 9University of Cleveland, Gastroenterology, Cleveland, Ohio, United States, 10Cleveland Clinic, Department of Anatomic Pathology, Cleveland, Ohio, United States, 11Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, New York, United States, 12Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States

1University of Washington Medical Center, Seattle, United States 2Arena Pharmaceuticals, Inc., San Diego, United States 3Virginia Mason, Digestive Disease Institute, Seattle, United States

DOP077

Immunomodulatory effects of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator

Year: 2017
Source:

1University of Washington Medical Center, Seattle, United States 2Arena Pharmaceuticals, Inc., San Diego, United States 3Virginia Mason, Digestive Disease Institute, Seattle, United States

Authors:

Lee S.D.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Chiorean M.3

1Asklepios Westklinikum Hamburg and Christian Albrechts University, Department of Internal Medicine/Gastroenterology, Kiel, Germany 2Arena Pharmaceuticals, Inc., San Diego, United States 3Nancy University Hospital and Lorraine University, Department of Gastroenterology, Nancy, France

DOP078

Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator

Year: 2017
Source:

1Asklepios Westklinikum Hamburg and Christian Albrechts University, Department of Internal Medicine/Gastroenterology, Kiel, Germany 2Arena Pharmaceuticals, Inc., San Diego, United States 3Nancy University Hospital and Lorraine University, Department of Gastroenterology, Nancy, France

Authors:

Kühbacher T.*1, Christopher R.2, Trokan L.2, Lassen C.2, Adams J.2, Peyrin-Biroulet L.3

DOP078

Risk of malignancy in paediatric inflammatory bowel disease: results from the DEVELOP registry

Year: 2016
Authors:

M. Dubinsky1, J. Hyams2, R. Baldassano3, R. Colletti4, S. Cucchiara5, J. Escher6, W. Faubion7, J. Fell8, B. Gold9, A. Griffiths10, S. Koletzko11, S. Kugathasan12, J. Markowitz13, F. Ruemmele14, G. Veerman*15, H. Winter16, N. Masel17, K. Tang18, M. Thayu18

1Mount Sinai, Icahn School of Medicine, New York, New York, United States, 2Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 3The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, 4University of Vermont Children’s Hospital, Burlington, Vermont, United States, 5Sapienza University of Rome/University Hospital, Rome, Italy, 6Erasmus Mc-Sophia Children’s Hospital, Rotterdam, Netherlands, 7Mayo Clinic, Rochester, Minnesota, United States, 8Chelsea and Westminster Hospital, London, United Kingdom, 9Children’s Centre for Digestive Health Care, Atlanta, Georgia, United States, 10Hospital for Sick Children, University of Toronto, Department of Paediatrics, Toronto, Canada, 11Ludwig Maximilians Universität München, Munich, Germany, 12Emory University, Atlanta, Georgia, United States, 13Cohen Children’s Medical Centre Of New York, New York, New York, United States, 14Hôpital Necker-Enfants Malades, Paris, France, 15Universitair Ziekenhaus, Brussels, Belgium, 16Mass General Hospital for Children, Boston, Massachusetts, United States, 17DOCS, Durham, North Carolina, United States, 18Janssen Scientific Affairs, LLC, Horsham, Pennsylvania, United States

DOP079

Predictors of first neoplastic colonic lesion in patients with inflammatory bowel disease undergoing colonoscopic surveillance

Year: 2016
Authors:

J. Kirchgesner*1, M. Svrcek2, C. Landman1, A. Bourrier1, 
I. Nion-Larmurier1, H. Sokol1, J. Cosnes1, J.-F. Flejou2, L. Beaugerie1

1Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, 2Saint-Antoine Hospital, AP-HP, Pathology, Paris, France

DOP080

Final results of a randomised study comparing high-definition colonoscopy alone with high- definition dye spraying and electronic virtual chromoendoscopy using iSCAN for detection of colonic neoplastic lesions during IBD surveillance colonoscopy

Year: 2016
Authors:

M. Iacucci*1, M. Fort Gasia1, A. Oluseyi1, R. Panaccione1, S. Gui X2, S. Urbanski3, P. Minoo3, S. Ghosh1

1University of Calgary, Gastroenterology, Calgary, Canada, 2University of Calgary, Pathology, Calgary, Canada, 3University of Calgary, Calgary, Canada

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & i3S – Instituto de Investigação e Inovação em Saúde, Glycobiology in Cancer, Porto, Portugal 2Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal 3Instituto de Investigação e Inovação em Saude (I3S)/Institute for Molecular and Cell Biology (IBMC), Immunobiology Group, Porto, Portugal 4Instituto de Investigação e Inovação em Saude (I3S)/ Institute of Biomedical Engineering (INEB), NEWTherapies Group, University of Porto, Porto, Portugal 5Centro Hospitalar do Porto, Multidisciplinary Unit for Biomedical Research (UMIB), Porto, Portugal 6Centro Hospitalar do Porto, Hematology Department, Porto, Portugal 7Medical Faculty, Centre for Research in HealthTechnologies and Information Systems (CINTESIS), Porto, Portugal 8Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal 9University of Porto, Medical Faculty, Porto, Portugal

DOP081

Glycosylation of T cells: a novel targeted-specific therapeutic strategy in IBD

Year: 2017
Source:

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & i3S – Instituto de Investigação e Inovação em Saúde, Glycobiology in Cancer, Porto, Portugal 2Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal 3Instituto de Investigação e Inovação em Saude (I3S)/Institute for Molecular and Cell Biology (IBMC), Immunobiology Group, Porto, Portugal 4Instituto de Investigação e Inovação em Saude (I3S)/ Institute of Biomedical Engineering (INEB), NEWTherapies Group, University of Porto, Porto, Portugal 5Centro Hospitalar do Porto, Multidisciplinary Unit for Biomedical Research (UMIB), Porto, Portugal 6Centro Hospitalar do Porto, Hematology Department, Porto, Portugal 7Medical Faculty, Centre for Research in HealthTechnologies and Information Systems (CINTESIS), Porto, Portugal 8Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal 9University of Porto, Medical Faculty, Porto, Portugal

Authors:

Dias A.M.*1,2, Correia A.3, Pereira M.1, Almeida C.R.4, Alves I.1, Lima M.5,6, Marcos-Pinto R.2,7,8, Reis C.A.1,2,9, Vilanova M.2,3, Lago P.8, Pinho S.S.1,9

DOP081

Outcomes of colitis-associated dysplasia after referral from the community to a tertiary centre

Year: 2016
Authors:

D. Rubin*, N. Krugliak Cleveland, D. Rodriquez

University of Chicago Medicine, Inflammatory Bowel Disease Centre, Chicago, Illinois, United States

1Safra Children's Hospital, Pediatric Gastroenterology, Tel Hashomer, Israel 2Boston Children's Hospital, Boston, United States 3University of Florida, Gainesville, United States

DOP082

Enhanced TH17 responses in patients with IL10 receptor deficiency and history of infantile-onset IBD

Year: 2017
Source:

1Safra Children's Hospital, Pediatric Gastroenterology, Tel Hashomer, Israel 2Boston Children's Hospital, Boston, United States 3University of Florida, Gainesville, United States

Authors:

Shouval D.*1, Konnikova L.2, Werner L.1, Nunberg M.1, Weiss B.1, Glover S.3, Snapper S.2

DOP082

Proximity extension assay immunoassay technology identifies novel serum biomarkers that can diagnose and classify inflammatory bowel diseases: IBD Character Consortium

Year: 2016
Authors:

R. Kalla*1, A. Ocklind2, C. Petrén2, N. Nordberg2, N. Kennedy1, N. Ventham1, E. Pettersson2, D. Bergemalm3, J. Lindström4, S. Vatn4, H. Hjortswang5, E. Nimmo1, H. Drummond1, P. Ricanek6, F. Dahl4, D. Wilson1, J. Jahnsen4, F. Gomollón7, M. Pierik8, J. Söderholm9, M. Vatn4, J. Halfvarson3, IBD Character Consortium1, J. Satsangi1

1University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, 2Olink, Bioscience, Uppsala, Sweden, 3Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, 4Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 5Linköping University Hospital, Department of Gastroenterology, Linköping, Sweden, 6Akershus University Hospital, Deaprtment of Gastroenterology, Lorenskog, Norway, 7University of Zaragosa, Gastroenterology, Zaragosa, Spain, 8Maastricht University Medical Centre (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, 9Linköping University Hospital, Department of Surgery, Linköping, Sweden

DOP083

Faecal calprotectin improves the predictive power of 3 practical indices for mucosal healing amongst patients with Crohn’s disease: results from PREDICT

Year: 2016
Authors:

W. Sandborn*1, R. Panaccione2, J.-F. Colombel3, E. Louis4, A. Robinson5, K. Wallace5, M. Bereswill6, M. Shapiro5, N. Chen5, M. Skup5, S. Wang5, R. Thakkar5, J. Chao5

1University of California, San Diego, La Jolla, California, United States, 2University of Calgary, Medicine, Calgary, Canada, 3Centre Hospitalier Universitaire de Lille, Lille, France, 4University of Liège, Liège, Belgium, 5AbbVie Inc., North Chicago, Illinois, United States, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

1University Hospital Tuebingen, Internal Medicine I, Tuebingen, Germany 2Novozymes, Bagsvaerd, Denmark 3Defensin Therapeutics, Copenhagen N, Denmark

DOP083

Recombinant subcutaneous human beta-Defensin 2 (hBD2) ameliorates experimental colitis in different in vivo models

Year: 2017
Source:

1University Hospital Tuebingen, Internal Medicine I, Tuebingen, Germany 2Novozymes, Bagsvaerd, Denmark 3Defensin Therapeutics, Copenhagen N, Denmark

Authors:

Mailänder-Sánchez D.1, Kjaerulf S.2, Sidelmann Brinch K.2, Andersen B.2, Stange E.F.1, Malek N.1, Nordkild P.3, Wehkamp J.*1

DOP084

Identification of a potential new prognostic biomarker to select inflammatory bowel disease patients that fail standard therapy

Year: 2016
Authors:

M. S. Pereira1, S. Campos1, A. M. Dias1, I. Pedroto2, C. A. Reis1, 3, L. Maia2, R. Marcos-Pinto2, 3, P. Lago2, S. S. Pinho*1, 3

1Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & Institute for Research and Innovation in Health (i3S), Porto, Portugal, 2Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal, 3Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal

DOP085

Ileocolonic involvement and diagnosis is related to fragments of the extracellular matrix measured in serum of patients with Crohn’s disease

Year: 2016
Authors:

J. H. Mortensen*1, M. D. Jensen2, J. Kjeldsen2, A. Krag2, M. Karsdal1, A.-C. Bay-Jensen1

1Nordic Bioscience, Biomarkers & Research, Herlev, Denmark, 2Odense University Hospital, Department of Gastroenterology, Odense, Denmark

DOP086

Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases

Year: 2016
Authors:

A. Buisson*1, 2, E. Vazeille1, 2, R. Minet Quinard3, M. Goutte1, 2, D. Bouvier3, F. Goutorbe1, B. Pereira4, N. Barnich2, G. Bommelaer1, 2

1University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, 2UMR 1071 Inserm/Université d’Auvergne; USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, 3University Hospital G. Montpied, Biochemistry laboratory, Clermont-Ferrand, France, 4GM – Clermont-Ferrand University and Medical Centre, Biostatistics Unit, Clermont-Ferrand, France

Institut Pasteur, Immunology Department, Paris, France

DOP087

Microbial colonization at weaning period determines colitis severity in adult mice

Year: 2017
Source:

Institut Pasteur, Immunology Department, Paris, France

Authors:

Al Nabhani Z., Dulauroy S., Polomack B., Eberl G.

DOP087

MMP degraded type III collagen is a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease

Year: 2016
Authors:

W. T. van Haaften*1, 2, J. H. Mortensen3, M. A. Karsdal3, A.-C. Bay-Jensen3, G. Dijkstra2, P. Olinga1

1University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands, 2University Medical Centre Groningen, Department of Gastro-enterology and Hepatology, Groningen, Netherlands, 3Nordic Bioscience, Biomarkers and Research, Herlev, Denmark

DOP088

Inflammatory biomarkers in serum discriminate Crohn’s disease and ulcerative colitis from healthy controls

Year: 2016
Authors:

E. Andersson*1, D. Bergemalm1, R. Kruse1, M. D’Amato2, D. Repsilber1, J. Halfvarson1

1Örebro University, Faculty of Medicine and Health, Örebro, Sweden, 2Karolinska Institutet, Department of Medicine, Solna, Sweden

DOP089

Microbiota profiles in treatment-naïve Norwegian IBD and non-IBD patients: part of the European Union IBD character consortium

Year: 2016
Authors:

P. Ricanek*1, S. Vatn1, T. Lindahl2, E. Ciemniejewska2, J. Jahnsen1, C. Casen2, M. H. Vatn1

1Akershus University Hospital, Department of Gastroenterology, Lørenskog/Nordbyhagen, Norway, 2Genetic Analysis AS, Oslo, Norway

Page: () 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ... 146 ()